"Precision CancerCare™ is a leading-edge clinical capability and has huge potential to improve outcomes for individuals with a serious cancer diagnosis."
- Cindy Warden, Head of Zurich Corporate Risk
Zurich Corporate Risk has announced the introduction of Precision CancerCare™ and Second Medical Opinion+ (provided by Further) for new policies or existing clients going through a rate retest, initially quoted from the 1st April 2025.
To access Zurich’s Precision CancerCare™ and Second Medical Opinion+ services, a patient’s cancer must be either not responding to the first line of treatment, diagnosed as stage 3 or 4, from an unknown primary source, or be a rare form of cancer with an incidence of less than 6/100.000 included on the Surveillance of Rare Cancers in Europe RARECARE list.
Precision CancerCare™ provides access to comprehensive genetic testing, which uses the latest tumour profiling technology and expert medical panels. By understanding the ‘genetic make-up’ of the cancer, the service provides a customised treatment plan specific to the molecular drivers of the tumour.
Furthermore, if a hereditary mutation is identified (that could affect children), family members are offered testing and counselling to help them make decisions about their health. Navigation assistance on clinical trials is included, and the service provides expert clinical reports which offer personalised guidance regarding cancer treatment options and advice.
Clients will also have access to Second Medical Opinion+ which assists with peace of mind when it comes to diagnoses or treatment plans. The service offers access to an independent evaluation of a diagnosis, treatment plan, or medical condition from a qualified medical professional other than an individual’s primary doctor.
Second Medical Opinion+ is available once per unique diagnosis, and support is offered to spouses/partners, as well as dependants aged 22 or younger.
Clients can access Precision CancerCare™ via the Second Medical Opinion+ service.
“Zurich is delighted to partner with Further Group to significantly enhance the value-added services available to our Group Risk customers. Precision CancerCare™ is a leading-edge clinical capability and has huge potential to improve outcomes for individuals with a serious cancer diagnosis,” said Cindy Warden, Head of Zurich Corporate Risk.
Frank Ahedo, CEO of Further, added: “We’re thrilled to strengthen our partnership with Zurich Insurance in the UK. We’ve truly found a partner that shares our passion for innovation and ambition to make a meaningful impact by supporting those facing critical healthcare challenges.”
